Central and Eastern European Oncology Group   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Gdańsk Poland (1983)

Organization Overview

First Clinical Trial
2004
NCT00211952
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Central and Eastern European Oncology Group | The Central and Eastern European Gynecologic Oncology Group

Active Ingredients

Drugs in Phase 3 Trials (3)

celecoxib (celebrex) (1 trial)

durvalumab (imfinzi) (1 trial)

selinexor (Xpovio) (1 trial)

Drugs in Phase 2 Trials (2)

apx005m (1 trial)

rucaparib (rubraca) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 5